Juan Carlos Almagro

Dr. Juan Carlos Almagro is an internationally-recognized expert in engineering and development of antibody-based therapeutics. He has been active in the Antibody and Protein Engineering fields since the beginning of the 1990s, with ten years of experience in academic settings and over ten years of experience in the Pharma/Biotech industry. In part with a grant from National Science Foundation, Dr. Almagro founded GlobalBio, Inc. to provide collaborative services in the areas of discovery, optimization and development of biologics.

Prior to founding GlobalBio, Dr. Almagro was a Senior Director at Pfizer and Research Fellow and Head of Antibody Design at Johnson and Johnson. There his work focused on development and application of technologies to engineer more stable and potent antibodies, with broader cross-reactivity and multi-specific binding capabilities. In academia, Dr. Almagro was Visiting Scientist at Florida International University, Affiliated Visiting Scientist at Fred Hutchinson Cancer Research Center, Visiting Professor at Simon Fraser University and Associate Professor and Group Leader at The National University of Mexico.

Dr. Almagro has authored over 70 publications, encompassing more than 50 peer-reviewed scientific articles, 6 book chapters, and 20 international patents. His main contributions include the study of structure-function relationships of antibodies, development of computational tools and databases for analyses of antibody sequences and structures, and cloning and study of natural antibody repertoires from a variety of species.

Dr. Almagro serves as reviewer in Immunology and Protein Engineering journals, as well as for grant agencies in several countries. He has participated in the Scientific Advisory Boards of several Biotech companies, has chaired and given talks and lectures at major domestic and international scientific meetings, and has been expert witness in several Intellectual Property litigations between large biopharma organizations.